Hana Biosciences to Present at BioSquare 2006
March 02 2006 - 8:30AM
Business Wire
Hana Biosciences (AMEX:HBX) announced today that Dr. Gregory Berk,
Senior Vice President & Chief Medical Officer, will present at
BioSquare 2006 in Geneva, Switzerland on Thursday, March 9th at
2:15 PM in Room 7 on the second level of the International
Conference Centre Geneva -- Switzerland. BioSquare offers a unique
platform for the top management of biotechnology companies to meet
with key research and business development executives from the
pharmaceutical, nutraceutical, agricultural, food, and finance
industries. About Hana Biosciences Hana Biosciences, Inc.
(AMEX:HBX) is a South San Francisco, CA-based biopharmaceutical
company that acquires, develops, and commercializes innovative
products to advance cancer care. The company is committed to
creating value by building a world-class team, accelerating the
development of lead product candidates, expanding its pipeline by
being the alliance partner of choice, and nurturing a unique
company culture. Additional information on Hana Biosciences can be
found at www.hanabiosciences.com. This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements involve
risks and uncertainties that could cause Hana's actual results to
differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on current expectations, forecasts and assumptions that are
subject to risks and uncertainties, which could cause actual
outcomes and results to differ materially from these statements.
Among other things, there can be no assurances that any of Hana's
development efforts relating to its product candidates will be
successful. Other risks that may affect forward-looking information
contained in this press release include the possibility of being
unable to obtain regulatory approval of Hana's product candidates,
the risk that the results of clinical trials may not support Hana's
claims, Hana's reliance on third-party researchers to develop its
product candidates, and its lack of experience in developing
pharmaceutical products. Additional risks are described in the
company's Annual Report on Form 10-KSB for the year ended Dec. 31,
2004. Hana assumes no obligation to update these statements, except
as required by law.
Hana Biosciences (AMEX:HBX)
Historical Stock Chart
From May 2024 to Jun 2024
Hana Biosciences (AMEX:HBX)
Historical Stock Chart
From Jun 2023 to Jun 2024